KANNAPOLIS, N.C., Dec. 13, 2023 /PRNewswire/ — Bright Path Laboratories, a US-based advanced drug development and manufacturing company is proud to announce their contribution to solving drug shortages for the domestic development and manufacturing of two critical cancer drugs: Carboplatin and Cisplatin.
Both cancer drugs are used in chemotherapy treatment protocols to treat patients with various forms of cancer and, because of the shortage many patients have been forced to have their treatment delayed or significantly modified. The issue of domestic drug shortages has reached historic levels and concerns continue to grow as treatments for many significant health issues are having a serious impact on patient care.
Bright Path is using its patented continuous flow advanced manufacturing platform to domestically manufacture these drugs at its state-of-the-art North Carolina research and development manufacturing facility.
“The necessity to reshore America’s pharmaceutical manufacturing has never been greater and Bright Path is honored to be part of this process,” said Tony Quinones, Co-Founder and Chief Executive Officer of Bright Path Laboratories. “Our transformative technology is changing the way America manufactures medicine, reducing our dependence on foreign pharmaceutical products and ultimately delivering to patients the medicine they need.”
